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EGFP-R12 containing a low level of endotoxin (ET), via the satisfactory ET removal of EGFP-SR prior to
ligation with the R12 peptide. Fusion proteins of EGFP with R12 and the D-isomer of R12 prepared by EPL
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Cell penetrating peptides (CPPs) have been employed as vectors
for the intracellular delivery of various molecules which have
difﬁculty in entering cells by themselves [1,2]. One of the most
desirable applications of CPPs would be the delivery of bioactive
proteins having therapeutic prospects [3]. However, contamination of
CPP-fusion proteins by the endotoxins (ETs) can be a potential
problem when the fusion proteins are expressed in Escherichia coli
(E. coli) [4].
ETs (lipopolysaccharides, LPS) are a major component of the outer
membrane of Gram-negative bacteria. ETs are known to induce a strong
response in the immune system. Disruption of bacterial membranes
upon the harvesting of recombinant proteins from E. coli leads to the
release of ETs from the membranes and the contamination of ETs in the
proteins of interest. Misleading interpretation of the results by the
contamination of ETsmay be obtained if using immune-associated cellsin the assay [5–7]. When ETs enter the blood circulation, they induce
various undesired physiological responses, such as the release of pro-
inﬂammatory materials, fever, coagulopathy, septic shock, and even
mortal outcome [8]. Therefore, the preparation of biological products
with a sufﬁciently low ET level is a crucial issue. Since ETs are negatively
charged, due to the phosphate groups in lipid A, that is a major
component of ETs [9], removal of ET fromcationic proteins is not aneasy
task [10]. Arginine-rich peptides, including oligoarginines and theHIV-1
Tat peptide, comprise a major class of CPPs. When these positively
charged peptides are employed as CPPs and CPP-fusion proteins are
expressed in E. coli, this concern of contamination of the ETs would also
be applicable.
Expressed protein ligation (EPL) is a posttranslational splicing of
protein segments that accompanies exclusion of an internal segment
(Intein) followed by spontaneous attachment of a lateral segment [11].
Intein-mediated EPL has already been employed to form conjugates of
proteins or peptides with proteins, peptides, unnatural amino acids,
ﬂuorophores and dendrimers [12–16]. This methodology is also
promising for the preparation of novel CPP-fusion proteins bearing
CPPs with various chemical structures including those composed of
non-gene-encoded amino acids (i.e., D-amino acids, etc.). However, only
limited information is available on the applicability of thismethodology
for the preparation of the CPP–protein conjugates [12–16].
In this report, we assessed the practicability of EPL through the
preparation of fusion proteins of the enhanced green ﬂuorescent
protein (EGFP) with the arginine 12-mer (R12) peptide, a represen-
tative oligoarginine CPP [17], as a model. Optimization of the ligation
efﬁciency, procedures to prepare the EGFP-R12 of low ET content, and
the internalization efﬁciency of the obtained EGFP-R12 were studied.
2250 H.-H. Yu et al. / Biochimica et Biophysica Acta 1798 (2010) 2249–22572. Materials and methods
2.1. Reagents
Theaminoacidderivatives andRinkamide resinwerepurchased from
the Peptide Institute (Osaka, Japan) and Novabiochem (Läufelﬁngen,
Switzerland). Other chemicals unless speciﬁcally noted were fromWako
Pure Chemicals (Osaka, Japan).
2.2. Synthesis of peptides
CG-R12 [NH2-Cys-Gly-(Arg)12-amide] and CG-dR12 [NH2-Cys-
Gly-D(Arg)12-amide] were synthesized by 9-ﬂuorenylmethyloxycar-
bonyl (Fmoc)-solid-phase peptide synthesis on a Rink amide resin as
previously reported [18]. For the preparation of FITC-CG-R12 [FITC-
GABA-Cys-Gly-(Arg)12-amide] and FITC-R12 [FITC-GABA-(Arg)12-
amide], a γ-aminobutyryl (GABA) residue was employed as a linker
connecting N-terminal FITC moiety to the arginine peptides. Depro-
tection of the peptides and cleavage from the resin were conducted by
the treatment of triﬂuoroacetic acid/1,2-ethanedithiol (95:5) for 3 h
at room temperature. The synthesized peptides were puriﬁed by high
performance liquid chromatography followed by lyophilization. The
ﬁdelity of the synthesized peptides was conﬁrmed by matrix-assisted
laser desorption ionization time of ﬂight mass spectrometry (MALDI-
TOF MS) using a Voyager-DE STR (Applied Biosystems).
2.3. Conjugation of EGFP to synthetic peptide using EPL
2.3.1. Preparation of EGFP-thioester (EGFP-SR)
A fusion protein of EGFP and mini-intein (derived fromMycobacte-
rium Xenopi gyrase A, Mxe GyrA) combined with a chitin-binding
domain (EGFP-Intein-CBD) was prepared by the intein-mediated
puriﬁcation with an afﬁnity chitin-binding tag (IMPACT) system (New
England Biolab, Ipswich, MA) [11]. The Intein-CBD element permits
the puriﬁcation of the fusogenic EGFP using a chitin bead column
followed by the on-column cleavage to generate a thioester of EGFP as
follows: DNA encoding EGFP was ampliﬁed from pEGFP-N1 using the
forward primer 5′-GCAGTCGACGGTACC-3′ and the reverse primer 5′-
GGTGGTTACTAGTGCATCTCCCGTGATGCACTTGTACAGCTCGTCC-3′. The
ampliﬁed cDNA was inserted into the NcoI and SpeI site on the pTXB3
vector to create an expression vector encoding the EGFP-Intein-CBD
(pTXB3-EGFP). No extra amino acidwas inserted between the EGFP and
intein as a spacer. The E. coli BL21 (DE3), transformedwith pTXB3-EGFP,
was grown in LB medium (800 ml) and the expression of the EGFP-
Intein-CBD was induced by the treatment with 0.4 mM isopropyl-β-D-
thiogalactopyranoside (IPTG) at 20 °C for 16 h. The E. coliwas harvested
by centrifugation and lysed in chitin binding buffer (20 mM Tris–HCl
containing500 mMNaCl, pH8.5)with sonication. The lysatewas loaded
on the chitin bead column to capture the EGFP-Intein-CBD protein. The
beads were washed with 20-bed volumes of the chitin binding buffer
and then incubated with 2.5-bed volumes of the chitin binding buffer
containing 100 mM sodium 2-sulfanylethanesulfonate (MESNA) at 4 or
20 °C for 24 h to allow on-column cleavage of the EGFP. The generated
EGFP-SR was eluted from the column with the ligation buffer (0.1 M
Tris–HCl containing 500 mM NaCl and 10 mM MESNA, pH 8.5), and
EGFP-SR was concentrated using a Vivaspin 4 centrifugal concentrator
PES (10,000 MWCO) (Sartorius Stedim Biotech, Goettingen, Germany)
at 4 °C. For the analysis of the MESNA induced cleavage efﬁciency, the
remaining resin (50 µl) after the protein elution was sampled and
subjected to SDS-PAGE using a 12.5% acrylamide running gel. The
puriﬁed EGFP-SR was quantiﬁed on the basis of the molar extinction
coefﬁcient at 488 nm (55,000 M−1 cm−1) [19].
2.3.2. Ligation of EGFP-SR with CG-R12
To obtain the optimized ligation conditions, EGFP-SR of different
concentrations (10, 25, and 50 µM) and CG-R12 (10 equiv. to EGFP-SR) was incubated in ligation buffer (0.1 M Tris–HCl containing
500 mMNaCl and 10 mMMESNA, pH 8.5) at various temperatures (4,
20, and 37 °C) for 36 h, and then the ligation efﬁciency was analyzed
from the band intensity of the SDS-PAGE using NIH Image J. The
obtained EGFP-CG-R12 was puriﬁed on a DEAE-Sepharose Fast Flow
column (0.5 ml) using 20 mM Tris–HCl containing 50 mM NaCl (pH
8.0) as the eluent. Dithiothreitol (DTT) was then added to the fraction
of EGFP-CG-R12 to yield a ﬁnal DTT concentration of 10 mM and the
mixturewas incubated at room temperature for 30 min. EGFP-CG-R12
was then concentrated on a Vivaspin 4 column (10,000 MWCO) and
the buffer was exchanged by the repetitive addition of 3× phosphate
buffered saline (PBS) prior to centrifugation to prevent aggregation of
the EGFP-CG-R12.
2.4. Expression and puriﬁcation of 6-His-tagged EGFPs (H6-EGFPs)
H6-EGFP, H6-EGFP-R12, and H6-EGFP-CG-R12 were prepared
using pET bearing respective H6-EGFP cDNAs. The E. coli BL21 (DE3)
transformed with these plasmids was grown in LB medium (800 ml).
IPTG (0.1 mM)was employed for the protein overexpression. The H6-
EGFP proteins were puriﬁed by a Ni-NTA resin column (Qiagen,
Hilden, Germany) (1 ml) according to the protocol by the manufac-
turer. Brieﬂy, E. coli cells were lysed in lysis buffer [50 mM NaH2PO4
containing 300 mM NaCl, 10 mM imidazole, and 10 mM 2-mercap-
toethanol (pH 8.0)]. The lysate was mixed with Ni-NTA resin (1 ml
for 800 ml cell culture) at 4 °C for 1 h. The resin slurry was then
transferred to a column and washed with washing buffer
[50 mM NaH2PO4 containing 300 mM NaCl, 20 mM imidazole, and
10 mM 2-mercaptoethanol (pH 8.0)]. Finally, bound proteins were
eluted from the column with elution buffer [50 mM NaH2PO4
containing 300 mM NaCl, 250 mM imidazole, and 10 mM 2-mercap-
toethanol (pH 8.0)]. The fraction containing the desired protein was
repetitively concentrated using a Vivaspin 4 column and diluted with
3× PBS to replace the buffer.
2.5. Endotoxin removal from proteins
2.5.1. Ion exchange columns
Resource S (methyl sulfonate) and HiTrap Q HP (quaternary
ammonium) pre-packed columns (GE Healthcare, Amersham, UK)
(column volume, 1 ml each) operated on the ÄKTA Explorer system
(GE Healthcare) were employed for the removal of ET. H6-EGFP-CG-
R12 was diluted in buffer A (20 mMMES containing 100 mMNaCl, pH
6.0) prior to loading onto Resource S. The columnwas ﬁrst elutedwith
buffer A (10 ml) and then with a gradient of 0–100% buffer B (20 mM
MES containing 2 M NaCl, pH 6.0) over 20 min (ﬂow rate, 1 ml/min).
When HiTrap Q HP was used for the puriﬁcation of H6-EGFP-CG-R12,
the protein was diluted in the buffer (20 mM Tris–HCl containing
50 mM NaCl, pH 8.0) and then loaded onto the column. The column
was eluted with the same buffer (ﬂow rate, 0.5 ml/min) and the
eluate that contained the desired protein was collected. For the
puriﬁcation of the EGFP-SR, the protein was diluted in buffer A
(20 mM Tris–HCl, pH 8.0), loaded on a column of HiTrap Q HP, and
eluted with a gradient of buffer B (20 mM Tris–HCl containing 1 M
NaCl, pH 8.0) over 20 min at the ﬂow rate of 0.5 ml/min.
2.5.2. Polymyxin B (PMX) column
Removal of the ET was conducted using a Detoxi-Gel Endotoxin
removal column (1 ml) (Pierce, Rockford, IL) following the manufac-
turer's protocol. The solution of proteins (H6-EGFP and H6-EGFP-CG-
R12 in 50 mM Tris–HCl containing 500 mM NaCl, pH 8.5; EGFP-SR in
50 mM Tris–HCl containing 500 mMNaCl and 10 mMMESNA, pH 8.5)
was applied to the column equilibrated with the same buffer and left
for 1 h at 4 °C. The protein was then eluted from the column by the
same buffer. Fractions containing the desired proteins were concen-
trated using a Vivaspin 4 column prior to the replacement of the
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500 mM NaCl and 10 mMMESNA, pH 8.5 (for EGFP–SR), as described
in Section 2.3, respectively.
2.5.3. On-column washing with Triton X-114
The E. coli lysate containing H6-EGFP-CG-R12 (from 800 ml
culture) was lysed in the lysis buffer and applied to the Ni-NTA
column (1 ml) similar to that described in Section 2.3. The column
was washed with 50-bed volumes of washing buffer containing 0.1%
Triton X-114 [20] followed by 20-bed volumes of the same buffer
containing no Triton X-114. H6-EGFP-CG-R12 was then eluted with
elution buffer and the fraction containing H6-EGFP-CG-R12 was
repetitively concentrated using a Vivaspin 4 column and diluted with
3× PBS to replace the buffer to yield 10.6 mg of the protein.
For on-column Triton X-114 washing of EGFP-Intein-CBD on the
chitin bead column, the lysate containing EGFP-Intein-CBD (from
2400 ml culture) was applied to the chitin bead column (24 ml) as
described in Section 2.3.1 prior to washing with 50-bed volumes of
20 mM Tris–HCl containing 500 mMNaCl (pH 8.5) and 0.1% Triton X-
114. The column was then washed with 20-bed volumes of 20 mM
Tris–HCl containing 500 mM NaCl (pH 8.5) and subjected to on-
column cleavage of the EGFP-Intein-CBD at 4 °C as described in
Section 2.3.1 to generate the EGFP-SR (6.0 mg).
2.6. Endotoxin assay
The Endospecy LAL kit and endotoxin standard (E. coli O133) were
both purchased from Seikagaku Biobusiness (Tokyo, Japan), and the
ET contents in the proteins were analyzed by a chromogenic limulus
amebocyte lysate (LAL) test following the instructions from the
manufacturer. The proteins for the assay and ET standard were
titrated in various concentrations using ET-free water. Each titration
(40 µl) of the proteins was mixed with an equal volume of freshly
prepared LAL reagent in a 96-well microplate. After standing for
30 min at 37 °C, solutions of sodium nitrite, sulfamic acid and N-(1-
naphthyl)ethylenediamine were added to the solution. Absorbance of
the samples at 570 nm was monitored by a Multiskan FC plate reader
(Thermo Scientiﬁc, San Jose, CA). The ET level of the proteins was
calculated using the ET standard curve.
2.7. Cell culture
Human cervical cancer-derived HeLa cells were purchased from
the Riken BRC Cell Bank (Ibaraki, Japan), and cultured in α-minimum
essential medium containing 10% heat-inactivated bovine serum [α-
MEM(+)] (Invitrogen, Eugene, OR). The cells were grown on 100-mm
dishes and incubated at 37 °C under 5% CO2.
2.8. Flow cytometry
HeLa cells (1×105 cells/well) were seeded in a 24-well microplate
and cultured in α-MEM(+) for 24 h. The cells were treated with each
protein (0.5 µM, 200 µl). The cells were washed three times with
100 µl of 0.5 mg/ml heparin in PBS and then detached by the
treatment with 0.01% trypsin at 37 °C for 10 min. The collected cells
were pelleted by centrifugation at 700×g for 5 min, washed twice
with PBS and ﬁnally resuspended in 400 µl of PBS. The cell-associated
ﬂuorescence was detected by laser excitation at 488 nm and emission
ﬁlter at 515–545 nm (10,000 events) on a FACS Caliburﬂow cytometer
(BD Biosciences, Franklin Lakes, NJ).
2.9. Confocal laser scanning microscopy (CLSM)
HeLa cells (3×105 cells/well) were seeded on 35 mm glass-
bottomed dishes (Iwaki, Tokyo, Japan) and cultured in α-MEM(+)
for 24 h. After complete adhesion, the cells were washed with α-MEM(+) and treated with 0.5 µM protein in α-MEM(+). After
incubation for 12 and 48 h, the cellular localization of the proteins was
analyzed without washing and after heparin washing using PBS
containing 0.5 mg/ml heparin by the FV300 CLSM system (Olympus,
Tokyo, Japan) without ﬁxation.
3. Results and discussion
3.1. Preparation of EGFP-CG-R12 using EPL
Intracellular protein delivery using CPPs usually employs conju-
gation of proteins with CPPs to ensure efﬁcient delivery, and this is
accomplished by the preparation of fusion proteins with CPPs using
E. coli expression systems [21–23] or chemical conjugation of these
molecules [24,25]. Since the control of chemical processes to yield
single forms of the conjugates is often difﬁcult, it seems likely that the
former approach is more preferably employed. However, expression
of the CPP-fusion proteins is sometimes difﬁcult due to the potential
toxicity of the CPPs to E. coli [24], and contamination of the ETs with
the CPP-fusion proteins is usually inevitable. The enhanced green
ﬂuorescent protein (EGFP) has been extensively employed as a model
protein to study the efﬁciency of the CPP-mediated delivery, distri-
bution into cells and the mechanisms of cellular uptake [21–25], and
here we also employed EGFP to assess the applicability of EPL to
obtain CPP-fusion proteins of low ET contents.
Intein mediated puriﬁcation with an afﬁnity chitin-binding tag
(IMPACT) systemwas employed to express EGFP bearing a C-terminal
intein element-chitin binding domain (CBD) tag (EGFP-Intein-CBD)
(Scheme 1A). Attachment of this tag allows puriﬁcation of the EGFP-
Intein-CBD by a chitin column and subsequent treatment of the EGFP-
Intein-CBD on chitin beads with thiol reagents yields an EGFP bearing
thioester at the C-terminus. Incubation of the thioester of EGFP with
CPPs bearing a cysteine (Cys) at the N-terminus would yield the EGFP-
CPP fusion proteins. The conjugation of EGFP to a CPP derived from a
human calcitonin ([C8]hCT8-32) fragment utilizing the IMPACT
system has been previously reported by Machova et al. and the
efﬁcient internalization of the CPP-ligated EGFP into bovine nasal
mucosa was achieved [16]. However, details of the optimal conditions
for ligation were not reported.
As depicted in Scheme 1A, procedures for the preparation of EGFP-
CG-R12 by the IMPACT system, in which the dodecaarginine amide
bearing a Cys–Gly segment at the N-terminus was employed as
a CPP to ligate the thioester of EGFP, are divided into four steps:
(i) expression of EGFP-Intein-CBD by E. coli, (ii) binding of EGFP-
Intein-CBD to the chitin column, (iii) induction of the on-bead
cleavage between EGFP and Intein-CBD by sodium 2-sulfanylethane-
sulfonate (MESNA), and (iv) ﬁnal ligation of R12 to EGFP. EGFP has a
lysine at the C-terminus and it was reported that the presence of Lys at
this position may accelerate the liberation of EGFP from the EGFP-
Intein-CBD by the hydrolysis during the expression in E. coli when
cultured at 30 or 37 °C [16]. Therefore, the IPTG induced expression in
our experiment was performed at the lower temperature of 20 °C for
16 h to avoid the possible hydrolysis of the EGFP-Intein-CBD.
The efﬁciency in the on-column cleavage to generate EGFP-SR was
assessed using MESNA. Considering that a higher concentration of
MESNA should increase the cleavage efﬁciency [12], incubation with
100 mM MESNA instead of that listed in the manufacturer's
speciﬁcation (50 μM) was employed. Incubation was conducted for
24 h by referring to previous reports [12,16]. When the efﬁciency of
the thiolysis of EGFP-Intein-CBD to yield EGFP-SR was analyzed by
SDS-PAGE, a considerable amount of the EGFP-Intein-CBD remained
uncleaved on the chitin column by the MESNA treatment at 4 °C
(Fig. 1, lane 1). On the other hand, almost all of the EGFP-Intein-CBD
was cleaved to yield EGFP-SR when treated at 20 °C (Fig. 1, lane 2).
The fractions of EGFP-SR obtained after treatment with MESNA at 4 °C
and 20 °C showed a single band on SDS-PAGE (Fig. 1, lane 4). Although
Scheme 1. Preparation of fusion proteins of EGFP and R12 via EPL and E. coli expression system. (A) Intein-mediated puriﬁcation with a chitin-binding tag (IMPACT) system used for
the preparation of the EGFP-thioester (EGFP-SR). The fusion protein of EGFP with the Intein-chitin binding domain (CBD) segment was expressed in E. coli (EGFP-Intein-CBD). The
E. coli cell lysate was loaded onto the chitin column to allow binding of CBD to the chitin bead. On-column treatment of the EGFP-Intein-CBD with MESNA yielded EGFP-SR. Effective
removal of ET from EGFP-SR prior to the chemical ligation with CG-R12 yielded EGFP-CG-R12 of a low ET content. (B) The fusion protein bearing the corresponding sequence of
EGFP-CG-R12 in (A) but having the 6-His tag on its N-terminus (H6-EGFP-CG-R12) was expressed in the E. coli. The ETs were removed from the H6-EGFP-CG-R12 after puriﬁcation of
the protein on the Ni-NTA column.
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the thiol moiety was hydrolyzed, the fractions of EGFP-SR were
subjected to ligation with CG-R12 without further puriﬁcation at this
stage, and the conditions to yield a higher amount of the ﬁnal
compound were explored.
A time-course study of ligation using 50 µM EGFP-SR and 500 µM
CG-R12 in 0.1 M Tris–HCl containing 500 mM NaCl and 10 mM
MESNA (pH 8.5) suggested that the ligation reached almost
completion after 24 h even when incubated at 4 °C (data not
shown). Therefore, the incubation time of 36 h was employed in the
following experiments to ensure completion of the ligation. To assess
the effect of temperature on the ligation, the ligationwas conducted at
4, 20 and 37 °C using 50 µM EGFP-SR and 500 µMCG-R12. The ligation
yields at the respective temperatures were almost comparable (87–
92%) when analyzed by SDS-PAGE, and 20 °C, which yielded the
highest amount of product, was thus employed for incubation in the
later study. On the other hand, a signiﬁcant dependence of the ligation
efﬁciency on the EGFP-SR concentration was observed. The ligation
yield of EGFP-SR with a 10 molar equivalent of CG-R12, analyzed by
SDS-PAGE, was elevated from 77% to 92% with the increase in theEGFP-SR concentration from 10 to 50 µM. No signiﬁcant aggregation
of the proteins was observed even when 50 µM EGFP-SR and 500 µM
CG-R12 were employed. The SDS-PAGE after the ligation of 50 µM
EGFP-SR with 500 µM CG-R12 at 20 °C is shown in lane 5 of Fig. 1. An
intense band corresponding to the desired product EGFP-CG-R12
(upper band) as well as the trace amount of a band that may
correspond to EGFP (lower band) formed by the hydrolysis of EGFP-
SR during the MESNA treatment of the EGFP-Intein-CBD on the chitin
column and during the ligation of EGFP-SR and CG-R12 were
observed. The mixture was then subjected to DEAE-Sepharose
puriﬁcation to remove the EGFP and yield EGFP-CG-R12 giving a
single band on SDS-PAGE (Fig. 1, lane 6). The mass of EGFP-CG-R12
was further conﬁrmed by MALDI-TOF MS [(M+H)+ 28965.4
(theoretical 28974.9)]. As for the ligation of EGFP-SR with CG-R12,
EGFP-SR obtained by the treatment of EGFP-Intein-CBD with MESNA
at 4 °C to yield 93% EGFP-CG-R12 when analyzed from the band
densities of the SDS-PAGE (Fig. 1, lane 5) whereas it was 85% for the
EGFP-SR obtained from the treatment of the EGFP-Intein-CBD with
MESNA at 20 °C. However, considering that a signiﬁcant amount of
the EGFP-Intein-CBD remained uncleaved on the chitin column in the
Fig. 1. Monitoring the reactions involved in EPL to form EGFP-CG-R12. The EGFP-Intein-
CBD remaining on the chitin column after theMESNA treatment at 4 °C (lane 1) and 20 °C
(lane 2) were eluted and analyzed by SDS-PAGE. The obtained EGFP-SR (50 µM) was
ligated with the chemically synthesized CG-R12 peptide (500 µM) at 20 °C for 36 h, and
the productswere puriﬁed byDEAE-Sepharose. The results using EGFP-SR obtained by the
MESNA treatment at 4 °C are shown: EGFP-SR before ligation (lane 4); the product after
chemical ligation (lane 5); the product after puriﬁcation on the DEAE-Sepharose (lane 6).
Lane 3, size marker.
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treatment of EGFP-Intein-CBD with MESNA at 20 °C may attain a
higher overall yield of the EGFP-CG-R12.
3.2. Endotoxin removal from the EGFP-R12 fusion proteins
ETs are stable at various pHs and temperatures used for the protein
expression from E. coli [8]. Many chromatographic techniques,
including ion exchange chromatography and afﬁnity chromatogra-
phy, such as immobilized histidine, poly-L-lysine, poly(ethylenei-
mine) and polymyxin B (PMX), have been employed for the removal
of ET [26–28]. However, even after puriﬁcation through these
chromatographies, the complete removal of the ETs is sometimes
difﬁcult and the non-speciﬁc adsorption of the proteins on the
separation columns may accompany a considerable loss of the
products [9].
Prior to analyzing the ET contents in the CPP-fusion proteins
obtained by EPL, we assessed those in the proteins directly expressed
in E. coli. EGFP was also employed as a model of the cargo protein and
R12 as a CPP. Considering that a Cys–Gly sequence is inserted between
the EGFP and R12 segments in the fusion protein obtained from
the EPL (EGFP-CG-R12 as described above), and that insertion of the
6-His-tag would be beneﬁcial for the puriﬁcation of the expressedScheme 2. Trials for ET-removal from H6-EGFP (A), H6-EGFP-R12 (B), and EGFP-SR (C). Theproteins, a protein having H6-EGFP-CG-R12 was designed and
expressed in E. coli using the plasmid of the corresponding gene.
The H6-EGFP that lacks the CG-R12 segment was also prepared
(Scheme 1B).
The H6-EGFP-CG-R12 and H6-EGFP proteins conventionally
expressed from the E. coli were puriﬁed by a Ni-NTA column and
then subjected to the PMX column (Scheme 2A and B). In the case of
H6-EGFP, the PMX column was highly effective for the ET removal
(Scheme 2A). A single passage of the protein through the column
yielded a product of a highly reduced ET level (0.06 EU/µg protein),
indicating that the His-tag attached with EGFP was not an obstacle for
the ET removal (Table 1a). However, the attachment of the R12
segment with the protein signiﬁcantly reduced the recovery from the
PMX column (Scheme 2B).When H6-EGFP-CG-R12was applied to the
PMX column, there was no substantial recovery of the protein even by
the high salt elution using 50 mM Tris–HCl containing 2 M NaCl
(pH 8.5) (data not shown). Alternatively, almost 99% of the
contaminating ET in H6-EGFP-CG-R12 was removed by the puriﬁca-
tion on the anionic exchange column (HiTrap Q HP) (Scheme 2b).
However, the level of the remaining ET was still relatively high (14
EU/µg) and protein recovery was low (23%) (Table 1b). Even when
the proteinwas repuriﬁed again on the same column, there was only a
very small difference in the level of the contaminating ET (14 versus
10 EU/µg) together with a signiﬁcant loss in the proteins (recovery of
protein, 35%) (Table 1b′). The puriﬁcation by the cationic exchanger
Resource S (Scheme 2c) yielded similar results; 99% of the ETs was
removed by this column to yield the H6-EGFP-CG-R12 fraction
containing 19 EU/µg ETs (recovery of protein, 31%) (Table 1c).
Repetitive puriﬁcation using the same column slightly reduced the
amount of the contaminating ETs (13 EU/µg) together with a 42% loss
of the protein (Table 1c′). Non-ionic detergents including Triton X-
114 have been employed for the ET removal of proteins [29], and
successful elimination of the ETs from His-tagged proteins by Triton
X-114washing on the Ni-NTA columnwas reported [20]. However, an
unsatisfactory result was obtained by the same protocol to yield H6-
EGFP-CG-R12 containing 28 EU/µg ET (Table 1d). The above results
suggested the difﬁculty in removal of the ETs from proteins bearing
arginine-rich CPP sequences when the CPP fusion proteins are
expressed in E. coli.
On the other hand, when EPL is employed to obtain fusion proteins
with the CPPs, and if the ETs are effectively removed prior to the
ligation with the CPP segments, this unfavorable contact of the CPP
segments with the ETs can be avoided (Scheme 1A). This was
conﬁrmed by the following experiments as outlined in Scheme 2C.
EGFP-SR, obtained by the treatment of EGFP-Intein-CBD on a chitin
column with MESNA (Scheme 1A), was directly applied to the PMXresults from the trials shown by the letters in parentheses are listed in Tables 1 and 2.
Table 1
ET levels of H6-EGFP and H6-EGFP-CG-R12 after ET removal.
Samples Conditions of ET removal ET (EU/µg)
Methods Loaded protein (mg) Total ET (EU) Before After Protein recovery
H6-EGFP PMX (a) 1.3 50,000 109 0.06 66%
H6-EGFP-CG-R12 HiTrap Q HP (b) 1.47 2,200,000 1500 14 23%
HiTrap Q HP (b′) 0.24 3400 14 10 35%
Resource S (c) 1.53 2,300,000 1500 19 31%
Resource S (c′) 0.47 8900 19 13 58%
Triton X-114 washing (d) ND ND ND 28a NDb
The letters in parentheses correspond to those in Scheme 2. The b′ and c′ represent rechromatograph using the same columns. aThe ET content in the protein obtained after washing
with buffer instead of Triton X-114 on the Ni-NTA column was 1500 (EU/µg). bYield of the protein obtained after the Triton X-114 wash was comparable to that obtained after the
buffer washing; 10.6 mg of H6-EGFP-CG-R12 was obtained from an 800 ml culture after the Triton X-114 washing. The protein recovery (yield in puriﬁcation) was calculated on the
basis of the protein amounts before and after the puriﬁcations using the molar extinction coefﬁcient at 488 nm (55,000 M−1 cm−1).
Table 2
ET levels of EGFP-SR after ET removal.
Conditions of ET removal ET (EU/µg)
Methods Loaded protein (mg) Total ET (EU) Before After Protein recovery
EGFP-SR HiTrap Q HP (e) 0.36 2,160,000 6000 14 67%
PMX (f) 0.36 2,160,000 6000 0.01 80%
PMX (f′) 1.30 10,360,000 8000 34 86%
Combination of Triton X-114 washing and PXM
Triton X-114 washing (g) ND ND ND 1.1a NDb
PMX (h) 6.0 6600 1.1 0.08 101%
The letters in parentheses correspond to those in Scheme 2. The amount of protein loaded on the PMX column in f′was about three times as much as that in f. aThe ET content in the
protein obtained after buffer washing instead of the Triton X-114 wash on the Ni-NTA column was 1700. bComparable amounts of the proteins were obtained after the Triton X-114
or buffer washing on the Ni-NTA column. A 6.0 mg of EGFP-SRwas obtained from 2400 ml of the culture. The protein recovery (yield in puriﬁcation) was calculated on the basis of the
protein amounts before and after the puriﬁcations using the molar extinction coefﬁcient at 488 nm (55,000 M−1 cm−1).
Fig. 2. Cellular uptake of the fusion proteins of EGFP with the R12 peptides. The HeLa
cells were treated with 0.5 µM proteins in α-MEM containing 10% bovine serum. The
cells treated with the medium were used as the control. After incubation for 6, 12, 24
and 48 h, the ﬂuorescence derived from EGFP in the cells was analyzed by FACS. The
error bars represent the standard deviation (n=3).
2254 H.-H. Yu et al. / Biochimica et Biophysica Acta 1798 (2010) 2249–2257column. As expected, highly efﬁcient removal of ETs was achieved by
this single puriﬁcation step to obtain EGFP-SR containing less than 0.1
EU/µg ETs (Table 2f). The protein recovery in this puriﬁcation step
was also more than 80%. In addition, puriﬁcation using a HiTrap Q
column was also effective, but less efﬁcient than the PMX column;
EGFP-SR containing 14 EU/µg ETs was obtained with protein recovery
of 67% (Table 2e). However, by increasing the amount of proteins
charged on the PMX column, the efﬁciency of the ET removal
decreased (Table 2f′). In such a case, Triton X-114 washing of the
EGFP-Intein-CBD on a chitin column was found to be highly effective.
By this washing prior to the MESNA treatment, the ET level in the
resulting EGFP-SR fraction became 1.1 EU/µg (Table 2g). When a
column bound EGFP-Intein-CBD was washed with the buffer instead
of that containing 0.1% Triton X-114, the ET content in the resulting
EGFP-SR was 1700 EU/µg. The successive puriﬁcation of the former
sample using the PMX column accomplished the further removal of
the ETs to yield EGFP-SR containing 0.08 EU/µg ETs (Table 2h). In
addition, protein recovery after the PMX column puriﬁcation was
almost quantitative. Considering that almost 6 mg of the EGFP-SR was
ﬁnally obtained, addition of the Triton X-114 washing step of the
EGFP-Intein-CBD on the chitin column prior to the MESNA treatment
was highly effective, also applicable to the puriﬁcation on a relatively
larger scale of EGFP-SR. We also investigated whether the PMX
column puriﬁcation was effective for removing contaminating ETs
from Resource S-puriﬁed H6-EGFP-CG-R12 (Table 1c′). The PMX
column used in this study could be reused after repetitive washing
with 1% sodium deoxycholate as described in the manufacturer's
protocol. However, when the Resource S-puriﬁed H6-EGFP-CG-R12
was loaded on the PMX column that was once used and regenerated,
no substantial recovery of the protein was obtained. On the other
hand, efﬁcient removal of ETs from the same sample was accom-
plished using an unused column, giving satisfactory yield. These
results suggested that complete removal of the PMX-attached ETs
may be difﬁcult by detergent washing, and when the H6-EGFP-CG-
R12 was loaded on the regenerated PMX column, the remaining ETson the column strongly interacted with H6-EGFP-CG-R12 to retain it
on the column. Therefore, even when an unused PMX column is
employed for the R12-bearing proteins partially puriﬁed with, for
example, ion-exchange chromatography, increasing amount of the
loaded samples would easily saturate the PMX moiety on the column
with contaminating ETs to hamper the elution of the R12-bearing
proteins. We thus conclude that the approach using EPL should be
more reliable for the preparation of ET-free CPP-fusion proteins.3.3. Cellular uptake of the R12- or dR12-fused EGFP
We next examined the efﬁcacy of internalization of the prepared
proteins. EGFP fused with the D-isomers of R12 (EGFP-CG-dR12) was
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acids or non-gene-encoded amino acids is also an advantage of this
EPL-employing system.
HeLa cells were treated with EGFP-CG-R12 or EGFP-CG-dR12
(0.5 µM each) for 6, 12, 24 and 48 h, and the amount of protein taken
up by the cells was analyzed by ﬂow cytometry (Fig. 2). H6-EGFP-CG-
R12 and H6-EGFP conventionally expressed in E. coli were employed
as references. In this experiment, proteins of low ET contents as
described in Section 3.2 were employed. The efﬁciency of the cellular
uptake of EGFP-CG-R12 and EGFP-CG-dR12 was almost comparable to
or slightly higher than that of H6-EGFP-CG-R12. This ensured theFig. 3. Confocal microscopic observation of the HeLa cells treated with fusion proteins of EGF
10% bovine serum for 12 and 48 h. The cells were then analyzed using CLSMwithout washing
were treated with PBS containing 0.5 mg/ml heparin. Scale bar=20 µm. Red arrows indicat
plasma membranes.ability of the CPP-fusion proteins obtained by the EPL method to
internalize into the cells. The amounts of EGFP-CG-R12 and EGFP-CG-
dR12 taken up by the cells were about 7–8 and 5 times higher than
those of H6-EGFP after 12 and 48 h, respectively. Employment of the
D-form of R12 (dR12) as CPP of EGFP did not yield a marked difference
on the efﬁciency of cellular uptake compared with its L-isomer (R12).
Further assessment using different cargos should be necessary to
establish the efﬁciency of these CPPs. Considering that the chemical
cross-link has mainly been employed for the assessment of the
internalization efﬁciency of the CPP-protein conjugates, especially
when the CPPs contain non-gene-encoded amino acids, and thatP with R12. The cells were incubated with each protein (0.5 µM) in α-MEM containing
(left panels) or after heparin washing (right panels). For the heparin washing, the cells
e the EGFP-labeled vesicles and the green arrows show the EGFP proteins bound on the
2256 H.-H. Yu et al. / Biochimica et Biophysica Acta 1798 (2010) 2249–2257difﬁculties are often accompanied in quantitative and site-speciﬁc
modiﬁcation of the proteins by chemical ligation, employment of
this ligation method using EPL may open a way for the rational and
precise evaluation of the abilities of these CPPs as vectors for intra-
cellular protein delivery using the CPP-fusion proteins of unequivocal
structures.
During the course of this study, we encountered unexpected
results on the cellular uptake of H6-EGFP-R12—this protein was also
prepared by E. coli expression, but lacks the CG linker sequence to
connect EGFP and the R12 sequences. Cellular uptake of the H6-
EGFP-R12 protein was signiﬁcantly lower than that of H6-EGFP-CG-
R12. Therefore, the lack of two amino acids yielded a signiﬁcant
difference in cellular uptake of the proteins. Although further
studies are needed to clarify this observation, one possible reason
may be the effect of cysteine on the CPP-mediated cellular uptake. It
was recently reported by Aubry et al. that CPPs containing free
cysteines were more efﬁciently internalized than the CPPs lacking
cysteines via formation of disulﬁde bridges between the CPPs and
cell surface proteins [30]. To examine whether the cellular uptake of
the CG-R12 peptide is also more efﬁcient than the R12 peptide, cells
were treated with FITC-labeled CG-R12 or R12 peptides (FITC-CG-
R12 and FITC-R12) (1 μM each) for 1 and 3 h, respectively. However,
no signiﬁcant difference was observed for their cellular uptake
(data not shown). Without bearing the cargo proteins, these
peptides may efﬁciently internalize into cells and the reported
accelerating effect of cysteine for cellular uptake was not observed.
Without bearing cargo proteins, these peptides may internalize into
cells so efﬁciently that further effects of cysteine on cellular uptake
are not observed.
Live cell observation of HeLa cells treated with the above fusion
proteins of EGFP and R12 for 3 h using CLSM produced punctate
signals (Fig. 3, red arrows). Involvement of endocytosis including
macropinocytosis has been suggested [31,32] and these signals should
represent the endocytosed proteins. In addition, strong signals of
these proteins were observed at the peripheral of the cells (Fig. 3, left,
green arrows). Importance of the accumulation of the arginine-rich
CPPs to membrane-associated proteoglycans on their cellular uptake
has been pointed out, as well as the induction of macropinocytosis
[33]. These signals on the peripheral of the cells should reﬂect the cell
surface accumulation of these proteins and these were effectively
removed by heparin washing to facilitate the observation of the
signals from the proteins taken up by the cells (Fig. 3, right, red
arrows). In correlation with the results of the FACS analysis (Fig. 2),
protein signals in the cells and on cell surface were much weaker for
H6-EGFP-R12 lacking the CG segment than those having the CG
segment. Only very low signals were obtained in cells incubated with
H6-EGFP lacking the R12 segment.
4. Conclusion
In this study, we illustrated the usefulness of EPL for the
preparation of fusion proteins with arginine-rich CPPs of signiﬁcantly
low ET content by avoiding the unfavorable contact of the CPPs with
the ETs; our efforts failed to detach the CPPs from the ETs by ion-
exchange or PMX columns once the arginine-rich CPPs formed a
complex with the ETs. Considering the detrimental effects of
contaminating ETs, for example, to induce inﬂammatory responses
in clinical situations employing CPPs fused to therapeutic proteins,
this approachmay provide a practical way to eliminate the possibility.
This approach is also applicable to prepare fusion proteins with CPPs
composed of various amino acids including D-amino acids and peptide
mimetics. This feature should be beneﬁcial to design protein delivery
systems in vivo, using CPPs having targeting ability to, for example,
speciﬁc organs and tumors. We hope that this report could provide
useful information for future design of CPP fusion proteins with more
sophisticated properties.Acknowledgements
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